During the recent session, Novartis AG (NYSE:NVS)’s traded shares were 1.75 million, with the beta value of the company hitting 0.54. At the last check today, the stock’s price was $97.62, reflecting an intraday loss of -2.41% or -$2.41. The 52-week high for the NVS share is $105.56, that puts it down -8.13 from that peak though still a striking 24.1% gain since the share price plummeted to a 52-week low of $74.09. The company’s market capitalization is $228.98B, and the average intraday trading volume over the past 10 days was 1.76 million shares, and the average trade volume was 2.10 million shares over the past three months.

Novartis AG (NVS) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 2.20. NVS has a Sell rating from 3 analyst(s) out of 22 analysts who have looked at this stock. 9 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 8 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $1.66.

Novartis AG (NYSE:NVS) trade information

Novartis AG (NVS) registered a -2.41% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.41% in intraday trading to $97.62 this Wednesday, 05/24/23, hitting a weekly high. The stock’s 5-day price performance is -2.72%, and it has moved by -4.80% in 30 days. Based on these gigs, the overall price performance for the year is 6.19%. The short interest in Novartis AG (NYSE:NVS) is 4.78 million shares and it means that shorts have 2.17 day(s) to cover.

The consensus price target of analysts on Wall Street is $109.16, which implies an increase of 10.57% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $89.27 and $121.04 respectively. As a result, NVS is trading at a discount of -23.99% off the target high and 8.55% off the low.

Novartis AG (NVS) estimates and forecasts

Statistics show that Novartis AG has outperformed its competitors in share price, compared to the industry in which it operates. Novartis AG (NVS) shares have gone up 11.31% during the last six months, with a year-to-date growth rate more than the industry average at 9.34% against -5.90. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 6.40% this quarter and then jump 9.50% in the quarter after that. In the rating firms’ projections, revenue will increase 5.30% compared to the previous financial year.

Revenue for the current quarter is expected to be $13.16 billion as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $13.29 billion by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $12.78 billion and $12.54 billion respectively. In this case, analysts expect current quarter sales to grow by 2.90% and then jump by 6.00% in the coming quarter.

While earnings are projected to return -70.20% in 2023, the next five years will return 7.88% per annum.

NVS Dividends

Novartis AG is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Novartis AG is 3.50, with the dividend yield indicating at 3.50 percent, continuing the trend of increasing dividends in recent years.

Novartis AG (NYSE:NVS)’s Major holders

Novartis AG insiders own 0.01% of total outstanding shares while institutional holders control 8.25%, with the float percentage being 8.25%. Dodge & Cox Inc is the largest shareholder of the company, while 1,293 institutions own stock in it. As of Mar 30, 2023, the company held over 20.31 million shares (or 0.89% of all shares), a total value of $1.87 billion in shares.

The next largest institutional holding, with 16.43 million shares, is of Primecap Management Company’s that is approximately 0.72% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $1.51 billion.

Also, the Mutual Funds coming in first place with the largest holdings of Novartis AG (NVS) shares are Dodge & Cox Stock Fund and Vanguard/Primecap Fund. Data provided on Dec 30, 2022 indicates that Dodge & Cox Stock Fund owns about 14.91 million shares. This amounts to just over 0.65 percent of the company’s overall shares, with a $1.35 billion market value. The same data shows that the other fund manager holds slightly less at 10.44 million, or about 0.46% of the stock, which is worth about $947.39 million.